Therapeutics case studies

A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.

One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.

ICON’s proactivity in risk mitigation, commitment to the study, project planning and communication contributed significantly to the ultimate success of the study.

A sponsor needed to recruit nearly 500 patients for a pivotal study in an ultra rare disease. The study's demanding protocol posed significant difficulties for patients. ICON was able to revise the protocol, reducing patient burden, and implemented a global recruitment strategy and additional support that allowed recruitment to be completed ahead of schedule, saving the sponsor an estimated $700,000.

ICON provided a large pharma sponsor with consistent, accurate ECG and ECHO modality imaging, contributing to a breakthrough pulmonary arterial hypertension treatment.

Explore how we built a dedicated global infrastructure of functional hubs, reducing the cost per FTE by over 20% and resulting in 20% productivity savings.

An accelerated training program for Early Development Oncology CRAs was required to significantly increase the cohort of CRA talent across 7 countries globally.

A top ten pharmaceutical company needed clinical site support in an FSP model as it changed its pipeline to focus on complex oncology studies. The introduction of a Site Engagement Liaison delivered significant efficiencies and reduced risk.

A randomised, double-blind, placebo-controlled study on behalf of a biotechnology organisation to evaluate the safety, tolerability, and efficacy of the study drug in subjects with moderate to severe plaque psoriasis.

A pivotal phase 3 randomised, double-blind study to improve MASH and reduce progression to cirrhosis and/or hepatic decompensation, with high volumes of scans across two imaging modalities.

A large-pharma sponsor was looking for a medical imaging partner to support a four-year, phase 3 Multiple Myeloma study. This trial included 600 patients and 200 sites and required expedited start-up and turnaround times.

A large pharmaceutical sponsor required an accelerated medical imaging data delivery for regulatory submission on a phase 3 advanced and/or unresectable biliary tract carcinoma study that spanned 277 sites with 1,115 patients.